The Indian Patent Office has refused to grant a patent for dolutegravir. Dolutegravir is an important HIV medicine sold by Viv Healthcare. This will allow generic drugs to enter the market and become affordable. Will help expand access to life-saving treatment. The decision, announced after a controversial battle that lasted nearly a decade, comes after the company filed a patent application for HIV treatment in 2007.
According to the order accessed by TOI, the company faced several pre-grant protests from Natco and various advocacy groups between 2013 and 2019. This led to the patent office recently refusing the grant of the patent. Experts believe that this decision could serve as an example against the practice of “evergreen” patents.
A practice that extends the patent life of patent forms and improvements to life-saving drugs. In the next few years, with more players entering the market, first-line HIV drugs will likely be available at a fraction of the innovator price. “I am of the view that the claims are not patentable under section 3(d) of the Act as no enhanced therapeutic efficacy has been demonstrated in the specification,” the order by Deputy Controller D Usha Rao said.
Viev Healthcare, which is majority owned by GSK and whose major shareholders are Pfizer and Shionogi. Focuses on HIV treatments. In April 2014, Medicines Patent Pool and VIV Healthcare signed licensing agreements to accelerate access to dolutegravir for adult and pediatric care.
Viev Healthcare, which is majority-owned by GSK and whose major shareholders are Pfizer and Shionogi, focuses on HIV treatments. In April 2014, Medicines Patent Pool and VIV Healthcare signed licensing agreements to accelerate access to dolutegravir for adult and pediatric care.
Check out below Health Tools-
Calculate Your Body Mass Index (BMI)
